Establishment Labs Announces the Appointment of Dr. Brian Kinney to its Scientific Advisory Board


Establishment Labs, a global medical device company focused on breast implant technologies with a strong emphasis on product development and innovation, announced today that Brian Kinney, MD, FACS has joined its Scientific Advisory Board to assist the company in the advancement of its research and development of the next generation of Motiva breast implants. He will collaborate with experts recently appointed to the Medical Advisory Board.

In December 2015, Establishment Labs formalized its Scientific Advisory Board to continue and strengthen innovation across its Breast Implant portfolio and associated technologies. Innovation is at the foundation of Establishment Labs’ global strategy, and the company believes it will be a key factor in its efforts to bring the next generation of Motiva Implants to the United States.
Establishment Labs CEO, Juan José Chacón Quirós stated, “Dr. Kinney has unique expertise as a Plastic Surgeon and as an M.I.T educated Biomechanical Engineer. We are the first company in the world to incorporate super-silicones and biosensors in breast implants and with Dr. Kinney’s assistance, we will develop these technologies to extend product lifetime and prevent unnecessary operations to replace ruptured implants.”

Dr. Kinney added, “I am humbled and honored by the invitation to join the Scientific Advisory Board of Establishment Labs. Focusing on innovation should result not only in higher degrees of safety but also create a more natural look and feel that is desired by all patients. Neither patients nor surgeons should have to choose between safety and outcome.”

He continued, “While I believe that Establishment Labs’ most recent line of Ergonomix Implants are advanced and highly respected in the industry, I look forward to working with the Scientific Advisory Board innovation team to incorporate the state-of-the-art in biomaterials to further improve safety, performance of the implants and develop next generation technology.”
According to Rudy Mazzocchi, Executive Chairman of Establishment Labs, “Dr. Kinney’s knowledge is at the crossroads of Plastic Surgery and Biomechanical Engineering, precisely where our innovation team has been working to improve the safety and performance of silicone implants. Dr. Kinney will be a wonderful addition to our team and I am looking forward to working with him on our future product innovations.”

Dr. Kinney has a Bachelor of Science in Biomedical Engineering and a Master of Science in Mechanical Engineering from the Massachusetts Institute of Technology. He finished his Chief Residencies in General Surgery and Plastic Surgery at the University of California at Los Angeles. A Former President of the Plastic Surgery Educational Foundation and Chairman, Board of Trustees of the American Society of Plastic Surgeons, he is also member of the American Association of Plastic Surgeons (AAPS), the American Association for the Advancement of Science (AAAS), the American Cleft Lip and Palate Association (ACPA), the American College of Surgeons (ACS), the American Institute of Physics (AIP), , the American Society for Aesthetic Plastic Surgery (ASAPS), the American Society of Mechanical Engineers (ASME), the Institute of Electrical and Electronic Engineers (IEEE), the American Society of Plastic Surgeons (ASPS) and the Plastic Surgery Educational Foundation (PSEF).

About Establishment Labs:

Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants ( Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.